Article
BCR-ABL in chronic myelogenous leukemia--how does it work?
Acta haematologica - 1 Jan 2008
Goldman John M, Melo Junia V
Abstract excerpt
The discovery of the BCR-ABL fusion gene on the Philadelphia (Ph) chromosome in 1985 was the start of a new era in understanding the molecular basis of hematologic malignancies. It provided the rationale for producing first imatinib and then a series of small molecules designed to inhibit the tyrosine kinase activity of the Bcr-Abl oncoprotein, all of which can induce complete cytogenetic remissions in the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.